CD123 Monoclonal Antibody (6H6), PE-eFluor™ 610, eBioscience™, Invitrogen™

Description

• Description: The 6H6 monoclonal antibody reacts with human CD123, the alpha chain of the IL-3 receptor
• This 60-70 kDa transmembrane protein binds to IL-3 with low affinity by itself, and when associated with CD131 (common beta chain) binds IL-3 with high affinity
• CD123 is expressed by myeloid precursors, macrophages, dendritic cells, mast cells, basophils, and megakaryocytes
• Applications Reported: This 6H6 antibody has been reported for use in flow cytometric analysis
• Applications Tested: This 6H6 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells
• This can be used at 5 μL (0.125 μg) per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• PE-eFluor™ 610 can be excited with laser lines from 488-561 nm and emits at 607 nm
• We recommend using a 610/20 band pass filter (equivalent to PE-Texas Red™)
• Please make sure that your instrument is capable of detecting this fluorochome
• Light sensitivity: This tandem dye is sensitive to photo-induced oxidation
• Please protect this vial and stained samples from light
• Fixation: Samples can be stored in IC Fixation Buffer (cat
• 00-8222) (100 μL of cell sample + 100 μL of IC Fixation Buffer) or 1-step Fix/Lyse Solution (cat
• IL-3Ra (Interleukin-3 receptor subunit alpha) belongs to the type I cytokine receptor family and is a heterodimer with a unique alpha chain paired with the common beta (beta c or CDw131) subunit
• IL-3Ra is responsible for the transmission of signal of Interleukin-3
• IL-3Ra and IL-3Rb chain heterodimerization is induced by Interleukin-3, which is required for receptor activation but not high affinity binding
• IL-3Ra is also reported that IL-3Ra subunits are overexpressed on acute myeloid leukemia (AML) blasts compared with normal hematopoietic cells and are thus potential targets for novel therapeutic agents.